Computerized Cancer Research

With our advanced technology of CCR we have leaped forward and analyzed all aspects of this disease and a breakthrough drug is in the horizins to eradict this disease with the latest from  Osimertinib (also known as Tagrisso), a new drug from AstraZeneca, reducing the risk of patients with early-stage non-small cell lung cancer (NSCLC) dying by 51%.

That’s according to results from the Phase 3 ADAURA trial, which looked at 682 patients with early-stage NSCLC. They all had mutations of a gene that increased production of a protein called epidermal growth factor receptor (EGFR), which can help cancers grow.

We are working tirelessly to help the cancer communities in finding this solution.

For more information you may contact us at [email protected]